PRESCRIPTION INFORMATION. REFILLS. Is this a first dose? Yes No If No, when Is the prescriber enrolled in the Ultomiris REMS program? Yes No.
Ultomiris (ravulizumab rch) is to be included in the Black Triangle Scheme. The Product Information (PI) and Consumer Medicines Information (CMI) for Ultomiris
Alexion Pharmaceuticals Inc. ULTOMIRIS (Ravulizumab-cwvz): US Prescribing Information. 2024.
Ultomiris [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; March 2024. 2. National Organization for Rare Disorders
These highlights do not include all the information needed to use ULTOMIRIS safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous use Initial U.S. Approval: 2024 WARNING: SERIOUS MENINGOCOCCAL INFECTIONS See full prescribing information for complete boxed warning.
MEMBER PRESCRIBER INFORMATION: Authorization may be delayed if incomplete. o Conversion from Ultomiris (ravulizumab): When converting from
Information Pertaining to All Policies Forms. Coding Prescribing physician is enrolled in Soliris REMS program and or the Ultomiris REMS program.
Ultomiris information includes side effects, See the prescribing information for a full list of interactions. Ultomiris drug interactions (more detail) Storage
These highlights do not include all the information needed to use ULTOMIRIS safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous use . Initial U.S. Approval: 2024 _____ WARNING: SERIOUS MENINGOCOCCAL INFECTIONS See full prescribing information for complete boxed warning
Comments